NRSN and H1Z Related Headlines
Go Back- NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
- NeuroSense receives US patent for Alzheimer's treatment through 2043
- NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
- World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
- NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
- NeuroSense to Host Investor Webinar on December 8, 2025
- NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
- NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
- NeuroSense raises $500,000 in private placement at 40% premium
- NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
- NeuroSense Provides Business Update and Progress for the First Half of 2025
- Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
NRSN and H1Z Related Press Releases
Go Back- NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
- NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
- World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
- NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
- NeuroSense to Host Investor Webinar on December 8, 2025
- NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
- NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
- NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
- NeuroSense Provides Business Update and Progress for the First Half of 2025
- Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
